CELG is still cheap at .80 PEG vs AMGN & BIIB at 1.2 and 1.3. And on conservative 2016 numbers its 0.4 - so you get the best EPS growth in all of healthcare (and almost all S&P 500) for more than half off. Also Big Apremilast trial detail (Two seperate Phase 3 psoriasis trials) coming Mar 2 at AAD - could add $1 billion to analyst ests if PASI scores, safety and other data are as good as company seems to be indicating with their $1.5 to $2.0 billion in 2017 Apremilast ests - analysts still have to move up significantly once they see detaile data in 2 wks. and then the big MM-020 front line data that Citi said this week could add an AMAZING $3.31-$7.71 of INCREMENTAL EPS when front line MM sales peak in EU. This stock, despite its run, is VASTLY undervalued with many upside items (ests include generic Vidaza like they have for 2 yrs - still none in sight, ests include NO BUYBACKS - billions a yr will continue, ests include little for China,Mexico, Brazil, Russia, Turkey, South Korea Revlimid sales - approvals coming international sales very conservative, ests include only $500 million EU front line in 2017 - most see $3 billion+). Yes, this stock is vastly undervalued.